IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

REDA, GIANLUIGI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 6.790
NA - Nord America 5.268
AS - Asia 4.200
SA - Sud America 396
AF - Africa 122
OC - Oceania 30
Continente sconosciuto - Info sul continente non disponibili 5
Totale 16.811
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.088
DE - Germania 2.938
SG - Singapore 1.199
CN - Cina 1.192
GB - Regno Unito 1.075
IT - Italia 1.037
BD - Bangladesh 397
VN - Vietnam 393
SE - Svezia 334
BR - Brasile 300
RU - Federazione Russa 300
HK - Hong Kong 285
FR - Francia 254
IN - India 243
IE - Irlanda 165
NL - Olanda 154
CA - Canada 121
FI - Finlandia 110
TR - Turchia 107
UA - Ucraina 106
JP - Giappone 85
ID - Indonesia 71
KR - Corea 63
PL - Polonia 60
CI - Costa d'Avorio 51
ES - Italia 47
CH - Svizzera 45
EU - Europa 41
DK - Danimarca 35
MX - Messico 34
CO - Colombia 30
BE - Belgio 24
PH - Filippine 22
AR - Argentina 20
AU - Australia 20
CZ - Repubblica Ceca 20
GR - Grecia 20
ZA - Sudafrica 19
EG - Egitto 17
PK - Pakistan 16
AT - Austria 14
EC - Ecuador 14
MA - Marocco 14
IL - Israele 13
IQ - Iraq 13
TH - Thailandia 12
IR - Iran 11
SA - Arabia Saudita 11
NZ - Nuova Zelanda 10
RO - Romania 10
TW - Taiwan 9
MY - Malesia 8
AE - Emirati Arabi Uniti 7
PE - Perù 7
CL - Cile 6
LU - Lussemburgo 6
PY - Paraguay 6
VE - Venezuela 6
BG - Bulgaria 5
DO - Repubblica Dominicana 5
HR - Croazia 5
HU - Ungheria 5
KW - Kuwait 5
LT - Lituania 5
OM - Oman 5
PT - Portogallo 5
UY - Uruguay 5
ET - Etiopia 4
JM - Giamaica 4
NP - Nepal 4
UZ - Uzbekistan 4
AM - Armenia 3
AZ - Azerbaigian 3
BB - Barbados 3
DZ - Algeria 3
LB - Libano 3
LV - Lettonia 3
PS - Palestinian Territory 3
QA - Qatar 3
SN - Senegal 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AL - Albania 2
BO - Bolivia 2
CR - Costa Rica 2
JO - Giordania 2
KE - Kenya 2
KG - Kirghizistan 2
KZ - Kazakistan 2
PA - Panama 2
RE - Reunion 2
RS - Serbia 2
TN - Tunisia 2
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BS - Bahamas 1
BZ - Belize 1
CG - Congo 1
CW - ???statistics.table.value.countryCode.CW??? 1
GD - Grenada 1
GT - Guatemala 1
Totale 16.835
Salva come PNG Salva come JPEG
Città #
Frankfurt am Main 2.372
Southend 897
Singapore 764
Boise 589
Ashburn 568
Chandler 375
Milan 256
Hong Kong 254
Hanover 226
Beijing 210
San Jose 210
Dallas 181
Dublin 164
Fairfield 163
Princeton 135
Wilmington 128
New York 120
Council Bluffs 116
Hanoi 107
Seattle 106
Santa Clara 104
Ho Chi Minh City 102
Los Angeles 99
Ann Arbor 98
Woodbridge 95
Houston 94
Rome 80
Helsinki 73
Jacksonville 73
Bengaluru 68
Cambridge 66
Dearborn 66
Redwood City 65
Boardman 60
Lauterbourg 60
Buffalo 59
Toronto 58
Nanjing 55
Des Moines 54
Abidjan 51
Shanghai 51
Guangzhou 48
Payette 45
Jakarta 44
Tokyo 43
Warsaw 40
Istanbul 39
Berlin 37
Garden Valley 37
Phoenix 37
Moscow 36
Munich 34
Jinan 32
Cangzhou 31
Genoa 30
Redmond 30
The Dalles 30
Hefei 29
Jerome 29
Shenyang 29
São Paulo 28
Andover 25
Mountain View 25
Mumbai 25
Turin 25
Brussels 24
Orofino 24
Columbus 23
Nanchang 23
San Diego 22
Bari 21
Cottonwood 21
Da Nang 21
Tianjin 20
Bogotá 19
Changsha 19
Lewiston 19
Washington 19
Hangzhou 18
Kent 18
Sakarya 18
Deiva Marina 17
Hyderabad 17
Montreal 17
Serra 17
Atlanta 16
Fuzhou 16
London 16
Seoul 16
Chicago 15
Kiez 15
Madrid 15
Naples 15
Catania 14
Chennai 14
Ankara 13
Athens 13
Grafing 13
Hebei 13
San Francisco 13
Totale 10.894
Salva come PNG Salva come JPEG
Nome #
Low dose dasatinib in refractory imatinib mesylate chronic myeloid leukemia : case report 999
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine. Results of study on 486 cases outside clinical trials 499
Concomitant Occurrence of Blastic Plasmacytoid Dendritic Cell Neoplasm and Acute Myeloid Leukaemia after Lenalidomide Treatment for del(5q) Myelodysplastic Syndrome 493
Assessment of the 4-factor score : Retrospective analysis of 586 CLL patients receiving ibrutinib : A campus CLL study 470
FZD6 triggers Wnt-signalling driven by WNT10BIVS1 expression and highlights new targets in T cell acute lymphoblastic leukemia 435
Immunoglobulin heavy chain variable region gene (IGHV) and prediction of time to first treatment (TTFT) in patients with chronic lymphocytic leukemia (CLL): Mutational load or mutational status? Analysis of 1003 cases 414
Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL) : results of a prospective, single-arm multicentre study 402
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia : a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus 393
TP53 disruption as a risk factor in the era of targeted therapies: a multicenter retrospective study of 525 chronic lymphocytic leukemia cases 369
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases 341
Ensuring continuity of care of hematologic patients during COVID-19 pandemic in a tertiary hospital in Lombardy (Italy) 339
Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment 328
Ineffective hematopoiesis and markers of angiogeneisis in myelodysplastic syndromes 303
Frequency and clinical relevance of coding and noncoding NOTCH1 mutations in early stage Binet A chronic lymphocytic leukemia patients 283
Bendamustine in combination with ofatumumab in relapsed or refractory chronic lymphocytic leukemia : a GIMEMA multicenter phase II trial 282
High rate of MRD-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2) 279
Biological and molecular characterization of a rare case of cutaneous Richter syndrome 278
High levels of vascular endothelial growth factor protein expression are associated with an increased risk of transfusion dependence in myelodysplastic syndromes 272
IgA hypogammaglobulinemia predicts outcome in chronic lymphocytic leukemia 272
Acute idiopathic polyneuropathy after subcutaneous alemtuzumab (AL) therapy in chronic lymphocytic leukemia (CLL) patients 267
Multifactorial neutropenia in a patient with acute promyelocytic leukemia and associated large granular lymphocyte expansion: A case report 262
Off-Label Use of Thrombopoietin Receptor Agonists: Case Series and Review of the Literature 260
Evalutation of TIE2-expressing monocytes in myeloid disorders 254
Lenalidomide in the treatment of chronic lymphocytic leukemia 253
Efficacy of front-line ibrutinib and rituximab combination and the impact of treatment discontinuation in unfit patients with chronic lymphocytic leukemia : results of the Gimema LLC1114 Study 251
Predictors of atrial fibrillation in ibrutinib-treated CLL patients : a prospective study 250
Conjunctival hemorrhagic events associated with imatinib 246
Low dose campath 1-H is highly effective and safe in advanced chronic CLL 246
Impact of bone marrow fibrosis in response to azacitidine in 94 patients with myelodisplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia 243
Targeting WNT10B-Driven Signalling through Induction of FZD6 By Porcupine Inhibition in T Cell Acute Lymphoblastic Leukemia 240
Hepcidin levels and their determinants in different types of myelodysplastic syndromes 235
Reduced expression of toll-like receptor 4 in B-chronic lymphocytic leukemia patients with autoimmune complications 235
Guillain Barrè syndrome in a chronic lymphocytic leukaemia (CLL) patient after subcutaneous alemtuzumab (A) therapy 233
Lenalidomide treatment of myelodysplastic syndromes with chromosome 5q deletion : results from the National Registry of the Italian Drug Agency 233
Low-dose Alemtuzumab in Refractory/Relapsed Chronic Lymphocytic Leukemia : Genetic Profile and Long-term Outcome from a Single Center Experience 232
Comprehensive Biological and Molecular Characterization of a RARE Case of Cutaneous Richter Syndrome 232
Decitabine treatment for an unusual case of atypical chronic myeloid leukemia (aCML) with a concomitant chronic lymphocytic leukemia (CLL) 231
Impact of Bone Marrow Fibrosis and Early Response on Outcome after Azacitidine Therapy in 94 Patients with Myelodisplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia 228
Bone Marrow Fibrosis and Early Hematological Response as Predictors of Poor Outcome in Azacitidine Treated High Risk-Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia 224
Role of dasatinib in PH '-positive acute lymphoblastic leukemia (ALL) after imatinib-based therapy failure : a case report 221
Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab 220
Conjunctival hemorrhagic events associated with imatinib mesylate 219
Iron metabolism and erythropoietic stress in myelodysplastic sindrome 210
Treating chronic lymphocytic leukemia with obinutuzumab: safety and efficacy considerations 210
Low-dose subcutaneous campath (CAM) is highly effective and safe in advanced and chemotherapy-refractory B-CLL : results of a prospectic and multicenter phase II study 208
Low-dose ALEMTUZUMAB monotherapy in advanced chronic lymphocytic leukemia 200
Refractory and 17p-deleted chronic lymphocytic leukemia: improving survival with pathway inhibitors and allogeneic stem cell transplantation 196
Idelalisib rapidly improves platelet function tests in patients with chronic lymphocytic leukaemia 195
Relationship between expression of TLRS and disease activity in B-CLL 192
Myelodysplastic syndromes : microvascular density and immunohistochemical expression of the proteins controllin angiogenesis 191
Fludarabine-Ifosfamide-Rituximab (FIR): a therapeutic option for chronic lymphocytic leukemia patients resistant to Chlorambucil 191
Atypical primary cutaneous cryptococcosis during ibrutinib therapy for chronic lymphocytic leukemia 182
New SMAC-Mimetic Compounds Strongly Induce In Vitro Apoptosis of Human Lymphocytes From Patients with Chronic Lymphocytic Leukemia 182
Idelalisib Rapidly Improves Platelets Function in Patients with Chronic Lymphocytic Leukemia (CLL) 177
Atrial Fibrillation (AF) and Ibrutinib, a Monocentric Experience: Should Cardiological Evaluation be a Guide in Clinical Practice? 177
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study 176
Hypogammaglobulinemia in Chronic Lymphocytic Leukemia: A Predictor of Outcome? 175
Heminsight to assess patient reported outcomes of patients affected by chronic lymphocytic leukemia in daily clinical practice 174
Hypogammaglobulinemia is a strong predictor of time to first treatment in chronic lymphocytic leukemia 164
Secondary malignancies in chronic lymphocytic leukemia: a single centre retrospective analysis 155
Chronic lymphocytic leukemia and prognostic models : a bridge between clinical and biological markers 154
Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab 147
Lymphocytic infiltrate and p53 protein expression as predictive markers of response and outcome in myelodysplastic syndromes treated with azacitidine 142
Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report 139
Secondary Malignancies in Chronic Lymphocytic Leukemia: A Single Centre Retrospective Analysis of 514 Cases 137
Expression of TLRs in B-CLL: Relationship with Disease Activity 131
Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS) 130
Totale 17.301
Salva come PNG Salva come JPEG
Categoria #
all - tutte 39.381
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 39.381
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202197 0 0 0 0 0 0 0 0 0 0 0 97
2021/20221.370 113 92 266 62 92 59 72 91 133 93 85 212
2022/20231.490 186 145 140 154 132 250 43 92 185 33 87 43
2023/20242.431 38 78 75 55 169 120 359 332 177 318 357 353
2024/20252.875 341 411 248 364 163 76 107 189 125 224 194 433
2025/20264.612 429 265 413 366 463 264 574 145 392 262 591 448
Totale 17.301